Anti-bacterial drug Azithromycin, better known as ZPack, is saving people from Corona Virus death, not because it kills the virus, but rather, because it kills Chlamydia Pneumoniae bacteria which is causing the lung failure in the majority of hospitalized cases.
The connection was made by Indian doctor and Chlamydia Pneumoniae researcher Dr. Jaideep Dogra, MD, director of Central Govt. Health Scheme (CGHS), in Jaipur, India, and his son Dr. Luvdeep Dogra, a pediatrician studying Nephrology at Osmania University, in Hyderabad, as reported by India’s The Tribune.
Chlamydia pneumoniae (pictured above) is a type of bacteria that can cause respiratory tract infections, such as pneumonia, and is one cause of community-acquired pneumonia or lung infections developed outside of a hospital, according to the Centers for Disease Control. Not everyone exposed to Chlamydia pneumoniae will develop pneumonia, but in those that develop pneumonia, it can be fatal. (This is totally separate from the Chlamydia STD.)
According to the Indian doctors, Chlamydia Pneumoniae is also found in many heart disease patients, and dormant in around 10 per cent of the general population.
In patients then infected with Corona Virus, which attacks the immune system, weakening their defenses, Chlamydia Pneumoniae sets off a process of blood coagulation initiated in pulmonary arteries leading to a cardiac arrest or Hypoxia in which the patient is deprived of oxygen.
This X-ray image shows how lungs become inoperable once infected.
Researching the effects of Chlamydia Pneumoniae on heart patients in Rajasthan for two years, Dr. Jaideep Dogra had also published a paper in the International Journal of General Medicine.
Azithromycin is a long-known cure for the bacterial infection and his paper is posted on the National Institute of Health website.10.1.1.1016.2774
On the current research, the doctors said:
“Eighty-five per cent of Covid-19 patients having normal Influenza-Like Illness (ILI) symptoms get treated, while 10-15 per cent of patients develops sudden breathlessness and land in an emergency. In such patients, C. penumoniae probably gets activated when COVID-19 breaks down the patient’s immunity. This bacterial pathogen has a tendency, it gets activated, causes arterial thrombo (coagulopathy).”
Reviewing the postmortem study on Italian Corona Virus victims, they said:
“Autopsy studies on 38 subjects from two hospitals in Italy who died of COVID-19 were systematically analysed. A relevant finding of the presence of platelet-fibrin-thrombosis in small pulmonary arteries, which fits into the clinical context of a ‘Coagulopathy’ was present in a majority of these patients (86.8%, 33 out of 38). And, this was the turning point in the management of COVID 19”.
“If Azithromycin is administered in early stages of Corona infection in the optimum doses, the mortality risks of this dreaded disease may be minimised.”
Rather than the focus on delivering expensive ventilators to patients, whose condition “paradoxically worsened” while those with “simple non-invasive oxygen delivery did show recovery,” the immediate solution should be to focus on killing the bacteria.
“Evidence has been accumulating on the role of Chlamydia pneumoniae-a species of Gram-negative obligate intracellular pathogen (the link between virus and bacteria) which causes a spectrum of lower and upper respiratory tract infection in humans and has been implicated in etiology / pathogenesis of artery blockage,” the duo said.
The doctors hope to interest an American institution to be able to confirm their hypothesis with further research.
U.S. President Donald J. Trump has touted Azithromycine (pictured below under brand name Zithormax) as a one-two-three punch, along with Hydroxychloroquine (HCQ, below under brand name Plaquenil) and a Zinc vitamin supplement.
Although not formally approved by the FDA to treat the Corona Virus both pills are being prescribed, along with the zinc vitamin, as the best combination to treat the disease.
A study of 350 virus patients in France found regular breathing was restored in four hours, with zero intubations, hospitalizations or deaths.
The French scientists completed an open-label non-randomized clinical trial by Didier Raoult M.D/Ph.D et al found 100% of patients who received a combination of HCQ and Azithromycin tested negative and were virologically cured within six days of treatment.